TP53 and lung carcinoma: In addition, p38MAPK/AP kinase-2 (MK-2) was demonstrated to be responsible for cisplatin resistance in p53 deficient cells, indicating simultaneous targeting of p53 and MK-2 could be exploited to induce synthetic lethality in lung cancer [68,69].